Artículo

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance

Cordo Russo, Rosalia Ines Icon; Béguelin, W. ; Díaz Flaqué, María Celeste Icon; Proietti Anastasi, Cecilia Jazmín Icon; Venturutti, Leandro Icon; Galigniana, Natalia Maricel Icon; Tkach, Mercedes Icon; Guzmán, P. ; Roa, J.C. ; O'Brien, N.A. ; Charreau, Eduardo Hernan Icon; Schillaci, Roxana Icon; Elizalde, Patricia Virginia Icon

Otros responsables

Fecha

06/2015

Editorial

Nature Publishing Group

Revista

Oncogene

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0950-9232

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Membrane overexpression of ErbB-2/HER2 receptor tyrosine kinase (membrane ErbB-2 (MErbB-2)) has a critical role in breast cancer (BC). We and others have also shown the role of nuclear ErbB-2 (NErbB-2) in BC, whose presence we identified as a poor prognostic factor in MErbB-2-positive tumors. Current anti-ErbB-2 therapies, as with the antibody trastuzumab (Ttzm), target only MErbB-2. Here, we found that blockade of NErbB-2 action abrogates growth of BC cells, sensitive and resistant to Ttzm, in a scenario in which ErbB-2, ErbB-3 and Akt are phosphorylated, and ErbB-2/ErbB-3 dimers are formed. Also, inhibition of NErbB-2 presence suppresses growth of a preclinical BC model resistant to Ttzm. We showed that at the cyclin D1 promoter, ErbB-2 assembles a transcriptional complex with Stat3 (signal transducer and activator of transcription 3) and ErbB-3, another member of the ErbB family, which reveals the first nuclear function of ErbB-2/ErbB-3 dimer. We identified NErbB-2 as the major proliferation driver in Ttzm-resistant BC, and demonstrated that Ttzm inability to disrupt the Stat3/ErbB-2/ErbB-3 complex underlies its failure to inhibit growth. Furthermore, our results in the clinic revealed that nuclear interaction between ErbB-2 and Stat3 correlates with poor overall survival in primary breast tumors. Our findings challenge the paradigm of anti-ErbB-2 drug design and highlight NErbB-2 as a novel target to overcome Ttzm resistance.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa